Unbound Cloxacillin Concentrations During Continuous Infusion

Recruiting now · Phase 4

Conditions studied: Staphylococcal Infections

In brief

Cloxacillin is the first-line choice for the treatment of severe infections caused by the bacterium Staphylococcus aureus in Sweden. Over the past year, cloxacillin is increasingly administred through continuous infusion. In this study, the free (unbound) concentration of cloxacillin when administered as a continuous infusion will be measured to ensure that the free concentration is neither too high nor too low. A PK/PD model will be developed to predict which dosage of cloxacillin is appropriate for an individual based on age, gender, kidney function, and serum-protein level.

Key facts

Study ID

NCT06848387

Run by

Emeli Månsson

People needed

25

Starts

2026-01-14

Expected to finish

2027-12-01

Last updated by the study team

2026-02-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older
• Treating physician has decided to start continuous infusion of cloxacillin

You may not qualify if…

• Unwilling or unable to provide written informed consent

Where it is running

• Västmanlands sjukhus Västerås — Västerås, Sweden (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.